^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    GnRH antagonist

    Related drugs:
    9d
    Case Report: Cutaneous metastatic mucin-producing prostate adenocarcinoma. (PubMed, Front Oncol)
    He was started on androgen deprivation therapy with relugolix...It also raises awareness of prostate cancer presenting as solitary cutaneous metastasis and calls attention to the potential value of PSA screening in select elderly patients. Recognizing uncommon cutaneous manifestations may lead to earlier diagnosis and improved management of advanced internal malignancies.
    Journal
    |
    NKX2-1 (NK2 Homeobox 1) • PAX8 (Paired box 8) • NKX3-1 (NK3 homeobox 1)
    |
    Orgovyx (relugolix)
    10d
    PRESTO: A Study of Androgen Annihilation in High-Risk Biochemically Relapsed Prostate Cancer (clinicaltrials.gov)
    P3, N=504, Completed, Alliance Foundation Trials, LLC. | Active, not recruiting --> Completed | Trial completion date: Jan 2026 --> Jun 2025
    Trial completion • Trial completion date
    |
    abiraterone acetate • prednisone • bicalutamide • apalutamide • Firmagon (degarelix) • leuprolide acetate for depot suspension
    15d
    Characteristics of tertiary lymphoid structures in prostate cancer and the impact of neoadjuvant therapy on their formation and maturation. (PubMed, Front Immunol)
    Flow cytometry evaluated immune infiltration in bicalutamide-treated mice, and anti-PD1 was combined with degarelix/bicalutamide in preclinical mouse model. NHT enhances TLS formation, maturation, and immune cell infiltration, suggesting a synergistic role for androgen deprivation in shaping the tumor immune microenvironment. The improved anti-tumor response with combined anti-PD1 and ADT highlights the potential of immunotherapy-endocrine therapy combinations as a promising treatment strategy for PCa.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    CD20 (Membrane Spanning 4-Domains A1) • CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule) • FOXP3 (Forkhead Box P3)
    |
    bicalutamide • Firmagon (degarelix)
    16d
    ELARIS EM-COC: Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsules/Tablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain (clinicaltrials.gov)
    P3, N=800, Active, not recruiting, AbbVie | Recruiting --> Active, not recruiting
    Enrollment closed
    22d
    A Study to Measure Pharmacokinetic (PK) Concentrations of Gonadotropin-Releasing Hormone Delivered by the OmniPod Pump (clinicaltrials.gov)
    P1, N=0, Withdrawn, Ferring Pharmaceuticals | N=180 --> 0 | Trial completion date: Jan 2026 --> Oct 2025 | Recruiting --> Withdrawn | Trial primary completion date: Jan 2026 --> Oct 2025
    Enrollment change • Trial completion date • Trial withdrawal • Trial primary completion date
    1m
    OPTIMAS: Optimal PSA Triggered Individual Management of Androgen Sensitive Prostate Cancer (clinicaltrials.gov)
    P2, N=160, Recruiting, University of Utah | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Orgovyx (relugolix)
    2ms
    RTOG 0815: Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer (clinicaltrials.gov)
    P3, N=1538, Completed, Radiation Therapy Oncology Group | Active, not recruiting --> Completed
    Trial completion
    |
    bicalutamide • triptorelin • goserelin acetate • flutamide • Firmagon (degarelix) • leuprolide acetate for depot suspension • Suprefact (buserelin acetate)
    2ms
    OPTIMAS: Optimal PSA Triggered Individual Management of Androgen Sensitive Prostate Cancer (clinicaltrials.gov)
    P2, N=160, Not yet recruiting, University of Utah
    New P2 trial
    |
    Orgovyx (relugolix)
    2ms
    Gas Challenge: Human Cerebral Blood Flow Regulation (clinicaltrials.gov)
    P1, N=110, Completed, University of Wisconsin, Madison | Recruiting --> Completed | Trial completion date: Jul 2026 --> May 2025 | Trial primary completion date: Jul 2025 --> Mar 2025
    Trial completion • Trial completion date • Trial primary completion date
    2ms
    Surgical Myomectomy Followed by Oral Myfembree Versus Standard of Care Trial (SOUL) (clinicaltrials.gov)
    P4, N=0, Withdrawn, University of Chicago | N=136 --> 0 | Terminated --> Withdrawn
    Enrollment change • Trial withdrawal
    2ms
    A Clinical Trial to Evaluate Efficacy and Safety of Elagolix Tablets in Women With Moderate or Severe Endometriosis-associated Pain (clinicaltrials.gov)
    P3, N=202, Completed, Nanjing Chia-tai Tianqing Pharmaceutical | N=330 --> 202 | Trial completion date: Sep 2026 --> Apr 2025 | Trial primary completion date: Sep 2026 --> Nov 2024 | Recruiting --> Completed
    Trial completion • Enrollment change • Trial completion date • Trial primary completion date
    2ms
    REVELUTION: RElugolix VErsus LeUprolide Cardiac Trial (clinicaltrials.gov)
    P2, N=94, Active, not recruiting, Emory University | Trial completion date: Jun 2025 --> Dec 2025
    Trial completion date
    |
    Orgovyx (relugolix) • leuprolide acetate for depot suspension